Quarterly Updates30 May 2026, 12:01 pm
Anlon Healthcare FY26: Revenue Up 43%, PAT Up 42%
AI Summary
Anlon Healthcare Ltd reported strong FY26 results with a 43% increase in revenue, 48% growth in EBITDA, and a 42% rise in PAT. Consolidated total income reached ₹172.22 Cr, EBITDA stood at ₹47.77 Cr, and PAT at ₹29.09 Cr. The company's growth was fueled by increased demand, operational efficiencies, and strategic acquisitions, including Bizotic Lifescience. Anlon Healthcare is focused on expanding its product portfolio and regulated-market presence, aiming for a 30% revenue CAGR over the next three years with EBITDA margins between 25-30%.
Key Highlights
- Anlon Healthcare's FY26 consolidated revenue grew by 42.98% to ₹172.22 Cr.
- EBITDA increased by 47.55% to ₹47.77 Cr, and PAT rose by 41.77% to ₹29.09 Cr.
- Acquisition of Bizotic Lifescience strengthens manufacturing and growth capabilities.
- Company aims for 30% revenue CAGR over the next three years.
- Anlon Healthcare is expanding its presence in pharmaceutical, nutraceutical, veterinary, and personal care sectors.
Price Impact
More from AHCL